Addex Therapeutics (FRA:APE) 3-Year RORE % : -84.38% (As of Mar. 2026)


What is Addex Therapeutics 3-Year RORE %?

Addex Therapeutics FRA:APE -13.41% 3-Year RORE % is -84.38 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,288 Biotechnology companies, Addex Therapeutics ranks worse than 93.01% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Addex Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -84.38%.

The industry rank for Addex Therapeutics's 3-Year RORE % or its related term are showing as below:

FRA:APE's 3-Year RORE % is ranked worse than
93.01% of 1288 companies
in the Biotechnology industry
Industry Median: -11.485 vs FRA:APE: -84.38

Addex Therapeutics  (FRA:APE) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Addex Therapeutics 3-Year RORE % Related Terms


Addex Therapeutics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics 3-Year RORE % Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.34 1.86 -27.04 -100.00 -72.80

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.50 -65.16 -66.05 -72.80 -84.38

FRA:APE vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Addex Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's 3-Year RORE % falls into.



Addex Therapeutics 3-Year RORE % Calculation

Addex Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.054--0.135 )/( -0.096-0 )
=0.081/-0.096
=-84.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -84.38 mean?
Addex Therapeutics (FRA:APE) has a 3-Year RORE % of -84.38 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Addex Therapeutics and its competitors. According to the industry distribution chart, Addex Therapeutics ranks #1198 out of 1288 companies in the Biotechnology industry, placing it in the top 93%.
Is Addex Therapeutics' 3-Year RORE % too high?
Addex Therapeutics' current 3-Year RORE % is -84.38. Based on the distribution chart, Addex Therapeutics ranks #1198 out of 1288 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Addex Therapeutics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #1198 out of 1288 companies for 3-Year RORE %. This places Addex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current 3-Year RORE % is -84.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 255% above its estimated fair value. The current 3-Year RORE % is -84.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current 3-Year RORE % is -84.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.